ISRCTN79170611已完成不适用
A multicentre, multinational, double blind, randomised, parallel group, placebo-controlled study of ethyl-eicosapentaenoate (EPA) in patients with Huntington's disease (HD)
axdale Ltd (UK)0 个研究点目标入组 0 人开始时间: 2003年2月3日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Written informed consent
- •2. Availability of a responsible family member or carer to look after the patient during the trial and ensure complete compliance
- •3. Diagnosis of HD in stage I
排除标准
- •Not provided at time of registration
研究者
相似试验
进行中（未招募）
不适用
A double blind, multicentre, multinational, randomized, double dummy, three-arm parallel-group comparative study of the efficacy, safety and tolerance of oral NXL103 (500 mg twice daily) versus NXL103 (600 mg twice daily) versus oral amoxicillin (1000 mg three times daily) in the treatment of community-acquired pneumonia in adultsCommunity-Acquired PneumoniaEUCTR2007-001735-66-DEovexel S. A.300
进行中（未招募）
不适用
A double blind, multicentre, multinational, randomized, double dummy, three-arm parallel-group comparative study of the efficacy, safety and tolerance of oral NXL103 (500 mg twice daily) versus NXL103 (600 mg twice daily) versus oral amoxicillin (1000 mg three times daily) in the treatment of community-acquired pneumonia in adultsMedDRA version: 9.1Level: LLTClassification code 10010120Term: Community acquired pneumoniaCommunity-Acquired PneumoniaEUCTR2007-001735-66-EEovexel S. A.300
进行中（未招募）
不适用
A multicentre, multinational, double-blind, randomised, parallel group, placebo controlled trial of ethyl-EPA ethyl-Icosapent in patients with Huntington s Disease - NDEUCTR2005-002088-98-ITAMARIN NEUROSCIENCE LTD240
进行中（未招募）
不适用
A double-blind, multi-center, multinational, randomized withdrawal study evaluating the efficacy and safety of SR58611A (350 mg q12) versus placebo in the prevention of depression relapse up to 1 year in patients with Major Depressive Disorder improved after 12 weeks of open treatment with SR58611A (350 mg q12) - CALYPSOpatients with major depressive disorderMedDRA version: 8.0Level: LLTClassification code 10018105EUCTR2005-004006-81-FIsanofi-aventis recherche & développement800
进行中（未招募）
不适用
A Clinical Trial to Evaluate the Effects of the drug Aztreonam Lysine for Inhalation in Patients with Cystic Fibrosis, Mild Lung Disease, and infection with the bacteria Pseudomonas aeruginosa (AIR-CF4)EUCTR2015-000395-97-Outside-EU/EEAGilead Sciences, Inc.157